Pharma Reaserch Prod Co Ltd (214450) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.085x

Based on the latest financial reports, Pharma Reaserch Prod Co Ltd (214450) has a cash flow conversion efficiency ratio of 0.085x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩61.53 Billion ≈ $41.70 Million USD) by net assets (₩723.88 Billion ≈ $490.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Pharma Reaserch Prod Co Ltd for the company's overall valuation and market capitalisation.

Pharma Reaserch Prod Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Pharma Reaserch Prod Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Pharma Reaserch Prod Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pharma Reaserch Prod Co Ltd ranked by their cash flow conversion efficiency. Explore Pharma Reaserch Prod Co Ltd (214450) cash earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Qingdao Huicheng Environmental Co Ltd
SHE:300779
-0.010x
Shenzhen China Micro Semicon Co. Ltd. A
SHG:688380
N/A
Getac Technology Corp
TW:3005
0.046x
Stolt-Nielsen Limited
LSE:0OHK
0.058x
Shanxi Meijin Energy Co Ltd
SHE:000723
0.052x
VGP NV
BR:VGP
-0.006x
Carmila SA
PA:CARM
0.034x
Jenoptik AG
F:JEN
0.034x

Annual Cash Flow Conversion Efficiency for Pharma Reaserch Prod Co Ltd (2015–2025)

The table below shows the annual cash flow conversion efficiency of Pharma Reaserch Prod Co Ltd from 2015 to 2025. View Pharma Reaserch Prod Co Ltd stock quote for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ₩723.88 Billion
≈ $490.56 Million
₩183.16 Billion
≈ $124.13 Million
0.253x +3.01%
2024-12-31 ₩569.44 Billion
≈ $385.90 Million
₩139.88 Billion
≈ $94.79 Million
0.246x +74.82%
2023-12-31 ₩462.19 Billion
≈ $313.22 Million
₩64.95 Billion
≈ $44.01 Million
0.141x -18.75%
2022-12-31 ₩343.50 Billion
≈ $232.79 Million
₩59.40 Billion
≈ $40.26 Million
0.173x -19.11%
2021-12-31 ₩305.44 Billion
≈ $206.99 Million
₩65.30 Billion
≈ $44.25 Million
0.214x +61.97%
2020-12-31 ₩245.42 Billion
≈ $166.32 Million
₩32.39 Billion
≈ $21.95 Million
0.132x +43.18%
2019-12-31 ₩209.07 Billion
≈ $141.69 Million
₩19.27 Billion
≈ $13.06 Million
0.092x +250.09%
2018-12-31 ₩197.62 Billion
≈ $133.93 Million
₩5.20 Billion
≈ $3.53 Million
0.026x -44.96%
2017-12-31 ₩178.85 Billion
≈ $121.21 Million
₩8.56 Billion
≈ $5.80 Million
0.048x +0.60%
2016-12-31 ₩171.64 Billion
≈ $116.32 Million
₩8.16 Billion
≈ $5.53 Million
0.048x -53.49%
2015-12-31 ₩156.75 Billion
≈ $106.23 Million
₩16.02 Billion
≈ $10.86 Million
0.102x --

About Pharma Reaserch Prod Co Ltd

KQ:214450 Korea Biotechnology
Market Cap
$2.32 Billion
₩3.42 Trillion KRW
Market Cap Rank
#5676 Global
#128 in Korea
Share Price
₩329500.00
Change (1 day)
-0.45%
52-Week Range
₩259000.00 - ₩609000.00
All Time High
₩711000.00
About

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more